

## PLATINUM INT'L HEALTH CARE FUND ARSN 107 023 530

## 31 October 2013

<u>FACTS</u>				FEES				
Portfolio Value		\$76.62 mn		Entry fee		Nil		
Fund commenced		10 November 2003		Exit fee		Nil		
Minimum investment		A\$20,000 or NZ\$25,000			Management Expense Ratio/			
Regular Investment P			\$200 or NZ\$250 per mth/qtr		Indirect Cost Ratio (MER/ICR)		(inclusive of investment &	
Income distribution date Annual, 30 June					administration cost	s)		
Unit valuation		Sydney Business	•	Brokerage paid		Nil		
Unit prices		Арр 1.5264	Red 1.5187	Buy/sell spread		0.5% total		
PERFORMANCE <sup>1</sup>		FUND %	MCCI 0/	PERFORMANCE C	SRAPH <sup>2</sup>			
			<u>MSCI %</u>	\$45,000 -				
1 month		(1.10)	2.57	<i>v</i> 13,000	Platinum Int'l He	ealth Care Fund 97.7	%	
3 months		(0.92)	(0.70)	\$40,000 -				
6 months		17.73	19.77	\$40,000			r	
Calendar year to date	e	30.93	42.03	\$35,000 -				
1 year		33.57	43.60	\$33,000				
2 years (compound p	.a)	25.92	32.36	\$30,000 -			<b>J</b>	
	•			\$50,000 -				
3 years (compound pa)		19.21	20.34	\$25,000 -	J.M.		J	
5 years (compound pa)		13.74	7.32	ş25,000 -	M N			
7 years (compound p	•	7.11	4.71	\$20,000	¥./ 🔹 🔰	M Nin		
Since inception (com	pound pa)	7.07	6.00		MS MS	CI AC World Health		
INVESTED POSITION <sup>3</sup>				\$15,000		78	8.9%	
	LONG %	<u>NET %</u>	CURRENCY %	2003	2005 2007	2009 2011	2013	
Australia	2.0	2.0	8.0					
Belgium	2.5	2.5		Source: Factset and	Platinum			
Brazil	1.6	1.6	1.6	TOP TEN POSITIC				
Denmark	3.6	3.6	4.8					
France	5.2	5.2		<u>STOCK</u>	COUNTRY	<u>INDUSTRY</u>	<u>%</u>	
Germany	5.7	5.7		Novartis AG	Switzerland	Pharmaceuticals	3.0	
Italy	4.9	4.9		Sanofi SA	France	Pharmaceuticals	2.9	
Japan	6.6	6.6	6.0	Teva Pharmaceutica	als United States	Pharmaceuticals	2.7	
Sweden	4.3	4.3	4.3	Qiagen	Germany	Health Equip & Ser		
Switzerland	11.0	11.0	11.0	AstraZeneca PLC	-	n Health Equip & Ser		
UK	8.2	8.2	8.3	Alere Inc	United States	Health Equip & Ser		
US	23.3	20.9	29.8	Roche Holding AG	Switzerland	Pharmaceuticals	2.3	
Total	78.9	76.5		Ipsen SA	France	Pharmaceuticals	2.3	
				Genmab A/S	Denmark	Pharmaceuticals	2.0	
				Pfizer Inc	United States	Pharmaceuticals	2.0	
				INDUSTRY BREAK				
Canadian \$			1.7	<u>SECTOR</u>		LONG %	<u>NET %</u>	
Euro			20.6	Pharmaceuticals		45.6	45.6	
HK\$			1.2	Health Equipment 8	& Services	12.3	12.3	
Norwegian Krone			1.0	Biotechnology		10.3	10.3	
Singapore \$			1.7	Misc Manufacturing		3.5	3.5	
Cash & Accruals	21.1		400.5	Healthcare Provider		3.4	3.4	
Total	100.0	100.0	100.0	Electrical Equipmen	τ	2.0	2.0	
Long - 52 stocks Short - 1				Chemicals		1.8	1.8 (2.4)	
capital return for the specified	l period. They are	net of fees and costs (ex	esent the combined income and cluding the buy-sell spread and	Equity Funds* *Includes index short po	sition		(2.4)	
any investment performance f	fee payable), pre-	tax, and assume the reinv		includes index short po	SILIUII			
that historical performance is	not a reliable indi	cator of future performa				3 565 006 AFSL 221935, tradir y and issuer of units in the Plati		
be negative (particularly in the	e short-term).		-	Care Fund (the Fund). The Pla	atinum Trust Product Disc	losure Statement No.8 and Su	pplementary	
inception relative to the MSCI	All Country Worl	d Health Care Net Index	),000 invested in the Fund since in A\$.	PDS (together PDS) provides details about the Fund. You can obtain a copy of the PDS from Platinum's website, www.platinum.com.au, or by contacting Investor Services on 1300 726 700				
The investment returns are ca They are net of fees and costs	lculated using the (excluding the bu	• Fund's unit price. Iy-sell spread and any inv	vestment performance fee	(Australian investors only), 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via Invest@platinum.com.au.				
payable), pre-tax and assume does not invest by reference to	the reinvestment	of distributions. It should	d be noted that Platinum	Before making any investment decision you need to consider (with your financial adviser) your particular investment needs, objectives and financial circumstances. You should refer to the				
Platinum's individual stock sel	lection process an	d as a result holdings wil		PDS when deciding to acquire, or continue to hold, units in the Fund.				
make-up of the Index. The Ind 3. The "Long %" represents the	e exposure of phy	sical holdings and long s		DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not been prepared taking into account any particular investor's or class of investor's investment				
represents the exposure of phy The "Currency %" represents t				objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. To the extent permitted by law, no liability is accepted				
account currency hedging.			Long derivative exposures are	for any loss or damage as a result of any reliance on this information. Platinum does not guarantee the repayment of capital, payment of income or the Fund's performance.				
included, however, short deriv				Platinum is a member of the				